Skip to content
All compound profiles

EVIDENCE PROFILE / PUBLISHED

NAD+

NAD+ is a nucleotide-derived redox coenzyme, not a peptide. Direct NAD+, precursors, and related vitamin forms are not interchangeable. A 2025 single-centre randomized study evaluated a short intravenous course in ischemic cardiomyopathy; a later retrospective commercial-setting pilot assessed tolerability. Neither establishes broad wellness or longevity benefit.

Aliases reviewed
Nicotinamide adenine dinucleotide, NAD
Sources checked
2026-09-15
Editorial status
published

Evidence at a glance

Human
LimitedOne single-centre randomized study and one retrospective pilot.
Animal/cell
Not rated
Approved medicine
Not rated

Summarises how much research the profile's sources report, and of what kind. It is not a verdict on the compound or on any catalogue material.

PREPPY BOY ASKS

“A familiar name can hide a different molecule, fragment, formulation, or evidence story.”

The catalogue name is a starting point, not proof of formulation or identity. It participates in redox reactions, energy metabolism, DNA-repair signaling, and enzyme systems including sirtuins and PARPs.

Identity

NAD+ is a nucleotide-derived redox coenzyme, not a peptide. Direct NAD+, precursors, and related vitamin forms are not interchangeable.

Biological mechanism or research interest

It participates in redox reactions, energy metabolism, DNA-repair signaling, and enzyme systems including sirtuins and PARPs.

Verified approved human uses

The reviewed human studies evaluated investigational direct NAD+ administration; they do not establish an approved use for the catalogue material.

Investigational human evidence

A 2025 single-centre randomized study evaluated a short intravenous course in ischemic cardiomyopathy; a later retrospective commercial-setting pilot assessed tolerability. Neither establishes broad wellness or longevity benefit.

Energy, anti-aging, detoxification, and addiction-treatment claims are broader than demonstrated findings for direct NAD+ administration.

Human versus animal or cell evidence

Cellular necessity and animal bioenergetic findings do not establish benefit from an exogenous 500 mg material in people.

Limitations and known risks

The retrospective pilot recorded gastrointestinal symptoms, increased heart rate, and chest pressure during NAD+ infusions. Product quality, interactions, and long-term outcomes remain incompletely characterized.

What this profile is—and is not

Concise source review published with formulation, jurisdiction, and evidence-strength limits; recheck before material revision.

This is sourced education, not medical advice or a personal-use recommendation. It does not validate the identity, purity, sterility, safety, or effectiveness of a catalogue material.